DAYA CNS, LLC

was established  to develop novel non-opioid pyridoindole platform, invented by Dr. Parthasarathi Rajagopalan, for the treatment of chronic pain and substance abuse disorders.

DAYA CNS, LLC

was established  to develop novel non-opioid pyridoindole platform, invented by Dr. Parthasarathi Rajagopalan, for the treatment of chronic pain and substance abuse disorders.

Daya CNS’s product pipeline comprises non-opioid, disease modifying medications for the treatment for neuropathies, arthritis, and drug addiction.

OPPORTUNITY AND UNMET NEED

Neuropathic pain (chemotherapy induced neuropathy, diabetic neuropathy, fibromyalgia, etc.), not only impairs quality of life, but ominously leads to disruption and discontinuation of cancer chemotherapy. Notwithstanding the fact opioid and methamphetamine abuse present a major socioeconomic burden, these drugs of abuse produce large number of deaths every year. Hence, new medications that will replace opioids are in high demand, and revenue for such medications is estimated to be in billions.

graphic-1

DDD-028

is a potent, disease modifying non-opioid medication for the treatment of chronic pain.

  • Patented small molecule with proven efficacy in many different pain models (neuropathy, arthritis, and inflammation).

  • DDD-028 is neuroprotective; it prevents nerve damage induced by chemotherapeutic drugs such as paclitaxel.

  • Early safety studies indicte that DDD-028 is well tolerated, induces no apparent  sedation, and is safe at the expected dose regimen.

DDD - 024

  • Patented small molecule with proven efficacy in methamphetamine self-administration model.

  • DDD-024 reversed drug-craving behavior in both female and male rats at low dose of 7 mg/kg.

  • DDD-024 does not suppress locomotor activity and induces no sedative effect.

CORE INNOVATION

Daya has discovered a proprietary platform technology comprising
three small molecule scaffolds that do NOT display any opioid activity.

The “DDD-028” platform primarily focuses on the treatment of chronic pain (neuropathic, arthritic, inflammatory, and visceral).

The “DDD-024” platform primarily focuses on the treatment of substance abuse disorders (opioids and amphetamines).

The “DDD-016” platform primarily focuses on the treatment of neuropsychiatric disorders (e.g., Schizophrenia).

Daya believes that the potential to provide a broad analgesic effect in various chronic and acute pain conditions devoid of opioid or cannabinoid characteristics and shows signs of neuro-protective qualities  making it a compelling pre-IND platform.